Comparing Three Different Techniques for Magnetic Resonance Imaging-targeted Prostate Biopsies: A Systematic Review of In-bore Versus Magnetic Resonance Imaging-transrectal Ultrasound Fusion Versus Cognitive Registration. Is There a Preferred...
Authors
Affiliations
Context: The introduction of magnetic resonance imaging-guided biopsies (MRI-GB) has changed the paradigm concerning prostate biopsies. Three techniques of MRI-GB are available: (1) in-bore MRI target biopsy (MRI-TB), (2) MRI-transrectal ultrasound fusion (FUS-TB), and (3) cognitive registration (COG-TB).
Objective: To evaluate whether MRI-GB has increased detection rates of (clinically significant) prostate cancer (PCa) compared with transrectal ultrasound-guided biopsy (TRUS-GB) in patients at risk for PCa, and which technique of MRI-GB has the highest detection rate of (clinically significant) PCa.
Evidence Acquisition: We performed a literature search in PubMed, Embase, and CENTRAL databases. Studies were evaluated using the Quality Assessment of Diagnostic Accuracy Studies-2 checklist and START recommendations. The initial search identified 2562 studies and 43 were included in the meta-analysis.
Evidence Synthesis: Among the included studies 11 used MRI-TB, 17 used FUS-TB, 11 used COG-TB, and four used a combination of techniques. In 34 studies concurrent TRUS-GB was performed. There was no significant difference between MRI-GB (all techniques combined) and TRUS-GB for overall PCa detection (relative risk [RR] 0.97 [0.90-1.07]). MRI-GB had higher detection rates of clinically significant PCa (csPCa) compared with TRUS-GB (RR 1.16 [1.02-1.32]), and a lower yield of insignificant PCa (RR 0.47 [0.35-0.63]). There was a significant advantage (p = 0.02) of MRI-TB compared with COG-TB for overall PCa detection. For overall PCa detection there was no significant advantage of MRI-TB compared with FUS-TB (p=0.13), and neither for FUS-TB compared with COG-TB (p=0.11). For csPCa detection there was no significant advantage of any one technique of MRI-GB. The impact of lesion characteristics such as size and localisation could not be assessed.
Conclusions: MRI-GB had similar overall PCa detection rates compared with TRUS-GB, increased rates of csPCa, and decreased rates of insignificant PCa. MRI-TB has a superior overall PCa detection compared with COG-TB. FUS-TB and MRI-TB appear to have similar detection rates. Head-to-head comparisons of MRI-GB techniques are limited and are needed to confirm our findings.
Patient Summary: Our review shows that magnetic resonance imaging-guided biopsy detects more clinically significant prostate cancer (PCa) and less insignificant PCa compared with systematic biopsy in men at risk for PCa.
Aloufi W, Al Mopti A, Al-Tawil A, Huang Z, Nabi G Cancers (Basel). 2025; 17(3).
PMID: 39941825 PMC: 11816062. DOI: 10.3390/cancers17030458.
Clinical feasibility of MRI-guided in-bore prostate biopsies at 0.55T.
Kaur T, Jiang Y, Seiberlich N, Hussain H, Wells S, Wei J Abdom Radiol (NY). 2025; .
PMID: 39794536 DOI: 10.1007/s00261-024-04783-x.
Jia H, Meng W, Gao R, Wang Y, Zhan C, Yu Y Biosensors (Basel). 2024; 14(12).
PMID: 39727845 PMC: 11674406. DOI: 10.3390/bios14120579.
Agrawal S, Patil V, Prasad V, Menon A, Pooleri G Indian J Urol. 2024; 40(4):229-234.
PMID: 39555426 PMC: 11567580. DOI: 10.4103/iju.iju_36_24.
Deng R, Liu Y, Wang K, Ruan M, Li D, Wu J BMC Med. 2024; 22(1):530.
PMID: 39533250 PMC: 11559106. DOI: 10.1186/s12916-024-03742-z.